10 years ago

Akarna Therapeutics Raises $15 Million for NASH Drug Development

  • Akarna Therapeutics, a UK- and US-based biopharmaceutical company, has secured $15 million in Series B funding

  • The round was led by Forbion Capital Partners, with participation from existing investors New Science Ventures and Third Point Ventures

  • The funds will be used to accelerate the development of Akarna's lead FXR agonist drug candidate, aimed at treating non-alcoholic steatohepatitis (NASH)

  • Akarna focuses on developing novel small molecule therapeutics for inflammatory and fibrotic diseases

  • NASH is a progressive form of fatty liver disease with no approved therapies, and Akarna's lead candidate is currently in preclinical toxicology and safety pharmacology studies.

      • ProblemHealthcare

      "making NASH, a progressive form of fatty-liver disease, more manageable by targeting inflammatory and fibrotic diseases"

      Solution

      "developing a FXR agonist drug candidate to treat non-alcoholic steatohepatitis (NASH) with human proof-of-concept studies"

      Covered on